Cover Image
市場調查報告書

出血:開發中產品分析

Hemorrhage - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 245979
出版日期 內容資訊 英文 31 Pages
訂單完成後即時交付
價格
Back to Top
出血:開發中產品分析 Hemorrhage - Pipeline Review, H1 2017
出版日期: 2017年03月15日 內容資訊: 英文 31 Pages
簡介

所謂出血是由於血液過度流出造成的疾病,主要原因有肝臟疾病和出血障礙,高血壓,傷害,動脈瘤等。主要的症狀有噁心和嘔吐,吞嚥障礙,協調能力喪失,意識不明,沉重的頭痛,刺痛等。

本報告提供全球各國治療出血所用的開發中產品開發情形相關分析,提供您開發中產品的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要(產品概要,功能機制,研究開發 (R&D) 的發展情形),最新的產業趨勢等資訊。

簡介

  • 分析範圍

出血概要

治療藥的開發

  • 出血開發中產品:概要
  • 出血開發中產品:比較分析

各企業開發中的出血治療藥

大學/研究機關研究中的出血治療藥

開發中產品的概要

  • 臨床實驗階段的產品
  • 初期階段的產品

出血治療藥:開發中的產品一覽(各企業)

出血治療藥:研究中的產品一覽(大學/研究機關)

出血開發治療藥的企業

  • Cellphire, Inc.
  • Digna Biotech, S.L.
  • Haemostatix Limited
  • QRxPharma Limited
  • Serendex Pharmaceuticals A/S
  • Thrombotargets Europe SL

出血:治療藥的評估

  • 單劑治療藥的情況
  • 標的別
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

  • DB-055
  • eptacog alfa (activated)
  • PeproStat
  • Protein for Hematological Disorders, Dermatology, Shock and Injury
  • Q-8008
  • Small Molecule for Postpartum Hemorrhage
  • Small Molecules to Block Kir 7.1 for Postpartum Hemorrhage
  • Thrombosomes
  • TT-111
  • TT-112
  • V-0801

出血治療藥:開發中產品的最新趨勢

出血治療藥:開發暫停的產品

出血相關產品的開發里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9035IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hemorrhage - Pipeline Review, H1 2017, provides an overview of the Hemorrhage (Hematological Disorders) pipeline landscape.

Hemorrhage is a disease which results in excessive bleeding. Causes of hemorrhage include liver disease, bleeding disorder, high blood pressure, injury and aneurysm. Symptoms include nausea or vomiting, difficulty swallowing, loss of coordination, loss of consciousness, severe headache and tingling or numbness.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hemorrhage - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Hemorrhage (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hemorrhage (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hemorrhage and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I, Phase 0 and Preclinical stages are 1, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 2 molecules, respectively.

Hemorrhage (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hemorrhage (Hematological Disorders).
  • The pipeline guide reviews pipeline therapeutics for Hemorrhage (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hemorrhage (Hematological Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hemorrhage (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hemorrhage (Hematological Disorders)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hemorrhage (Hematological Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hemorrhage (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Hemorrhage - Overview
  • Hemorrhage - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Hemorrhage - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Hemorrhage - Companies Involved in Therapeutics Development
    • Cellphire Inc
    • Haemostatix Ltd
    • Savara Inc
  • Hemorrhage - Drug Profiles
    • coagulation factor VIIa (recombinant) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ethinylestradiol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PeproStat - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Protein for Hematological Disorders, Dermatology, Shock, Injury, Trauma and Infectious Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule for Postpartum Hemorrhage - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Block Kir 7.1 for Postpartum Hemorrhage - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Thrombosomes - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Hemorrhage - Dormant Projects
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Hemorrhage, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Hemorrhage - Pipeline by Cellphire Inc, H1 2017
  • Hemorrhage - Pipeline by Haemostatix Ltd, H1 2017
  • Hemorrhage - Pipeline by Savara Inc, H1 2017
  • Hemorrhage - Dormant Projects, H1 2017

List of Figures

  • Number of Products under Development for Hemorrhage, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Targets, H1 2017
  • Number of Products by Stage and Targets, H1 2017
  • Number of Products by Mechanism of Actions, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top